CRBP - Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc.

500 River Ridge Drive
Norwood, MA 02062
United States
617 963 0100
https://www.corbuspharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 33

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Yuval Cohen Ph.D.	CEO & Director	890.67k	N/A	1975
Mr. Sean F. Moran CPA, M.B.A., CPA, MBA	Chief Financial Officer	579.05k	N/A	1958
Dr. Rachael Brake Ph.D.	Chief Scientific Officer	552.22k	N/A	1972
Ted Jenkins	Sr. Director of Investor Relations & Corp. Communications	N/A	N/A	N/A
Ms. Lindsey Smith	Head of Corp. Communications & Patient Advocacy	N/A	N/A	N/A
Ms. Christina Bertsch	Head of HR	N/A	N/A	N/A
Scott Constantine	Sr. Director & Head of Clinical Operations	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Corporate governance

Corbus Pharmaceuticals Holdings, Inc.’s ISS governance QualityScore as of 1 May 2023 is 7. The pillar scores are Audit: 9; Board: 4; Shareholder rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.